APC-driven colorectal cancer

Subtype of Colorectal cancer

Clinical / Scientific

APC loss stabilizes β-catenin and is the most common initiating event in chromosomal-instability CRC. Stemness and crypt regeneration programmes follow.

Core Biological Drivers

APC loss

β-catenin stabilization.

Key Pathways

Wnt/β-catenin

Scientific explanation

Canonical Wnt signalling stabilizes β-catenin, driving TCF/LEF . APC loss is a classic colorectal initiating event; the pathway also contributes to stemness in several tissues.

Cancer stemness

Scientific explanation

Stem-like programmes (Wnt, Notch, Hedgehog, ALDH, CD44) can support self-renewal, quiescence and therapy tolerance in a minority population.

MYC

Scientific explanation

MYC factors coordinate biomass accumulation, ribosome biogenesis, and glutamine use. Amplification or pathway activation is common.

Pathway Convergence

Target → pathway → downstream effect → biological consequence. Shared intersections are mechanistic maps, not protocols.

Inflammatory survival

Chronic cytokine tone activates NF-κB and STAT3 transcriptional programmes that favour survival, invasion and sometimes immune evasion.

Cytokines
↓
NF-κB / STAT3
↓
Survival and invasion genes
↓
Therapy-tolerant phenotype

Metabolic Vulnerabilities

Aerobic supports ATP, biomass and acidification even when oxygen is available. Extent varies by tumour and remains a vulnerability hypothesis rather than a uniform target.

Tumor Microenvironment

Disordered vasculature creates , HIF-1α stabilization, induction and immune-suppressive adenosine/lactate milieus.

Metastasis Module

, protease-mediated invasion, , circulating tumour-cell survival and organ-specific colonization form the metastatic cascade. Pre-metastatic niches and vascular permeability influence tropism.

Resistance Biology

Wnt-high stem fractions may persist through cytotoxic pressure in models.

Cancer Stemness

Wnt, Notch, Hedgehog, ALDH and CD44-associated programmes can mark stem-like fractions with quiescence and therapy tolerance. These markers are not interchangeable across tumour types.

Mechanism-Based Adjunctive Strategies

Compounds appear only where a mechanistic overlap exists for this cancer. Evidence tiers are not equivalent. Nothing here is a treatment recommendation.

Niclosamide

In VitroIn VivoMechanistically Plausible

Target / Mechanism

uncoupler in cestodes; mammalian models report , Wnt/β-catenin and modulation. Those host-signalling findings are investigational/preclinical.

Cancer relevance

Models report Wnt/β-catenin, and effects. Host signalling findings remain investigational.

Wnt / STAT3 signalling models. Convergence: Wnt/β-catenin, JAK/STAT, mTOR.

Celecoxib

Clinical / Human EvidenceIn VivoIn Vitro

Target / Mechanism

Selective -2 reducing PGE2. Relevant to -associated epithelial neoplasia; cardiovascular risk and lack of broad anticancer approval constrain interpretation.

Cancer relevance

-2/PGE2 biology is relevant in some epithelial neoplasias. Cardiovascular risk and lack of broad anticancer approval apply. Do not equate polyp or biomarker studies with tumour cure.

Inflammation-associated epithelial neoplasia research. Convergence: COX / inflammatory signalling, Angiogenesis.

Curcumin

In VitroMechanistically Plausible

Target / Mechanism

Polyphenol with promiscuous in-vitro NF-κB, and ROS effects. Bioavailability is poor; dish activity does not establish clinical anticancer efficacy.

Cancer relevance

In-vitro NF-κB/ effects are frequent. Poor bioavailability and absence of robust clinical anticancer efficacy keep this pathway-level.

Inflammatory-signalling dish models. Convergence: NF-κB, JAK/STAT.

Research Context

  1. CRC adenoma-carcinoma. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767. https://doi.org/10.1016/0092-8674(90)90186-I

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.